The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer: study design

AIMS: Cachexia, the wasting disorder associated with a wide range of serious illnesses including cancer, is a major cause of morbidity and mortality. There is currently no widely approved therapeutic agent for treating or preventing cancer-associated cachexia. Colorectal cancer and non-small cell lu...

Descripción completa

Detalles Bibliográficos
Autores principales: Stewart Coats, Andrew J., Srinivasan, Venkatesan, Surendran, Jayaraman, Chiramana, Haritha, Vangipuram, Shankar R. K. G., Bhatt, Nirajkumar N., Jain, Minish, Shah, Sandip, Ali, Irfhan A. B. H., Fuang, Ho G., Hassan, Mohammed Z. M., Beadle, John, Tilson, Julia, Kirwan, Bridget-Anne, Anker, Stefan D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3222831/
https://www.ncbi.nlm.nih.gov/pubmed/22207908
http://dx.doi.org/10.1007/s13539-011-0046-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3222831/
https://www.ncbi.nlm.nih.gov/pubmed/22207908
http://dx.doi.org/10.1007/s13539-011-0046-2

Ejemplares similares